In-Process R&D — Acquisition of Pre-Approval Asset
Expensing the fair value allocated to in-process research and development in a pharma acquisition.
| Account Name | Type | Debit ($) | Credit ($) |
|---|---|---|---|
| In-Process R&D Expense (IPR&D) | Expense (+) | 800,000,000.00 | - |
| Intangible Assets (Acquisition) | Asset (+) | - | - |
| Consideration Payable / Cash | Liability/Asset (-) | - | 800,000,000.00 |
💡 Accountant's Note
Under IFRS 3 (Business Combinations), IPR&D acquired in a business combination is recognised as an intangible asset at fair value even if it would otherwise be expensed. However, post-acquisition, any subsequent development expenditure on the acquired IPR&D compound is expensed as incurred. This entry represents a direct acquisition of a pre-approval compound (an asset purchase, not a business combination) where IPR&D is expensed.
Practitioner & Systems Framework
💻 ERP Architecture
The accounting treatment of acquired IPR&D depends critically on whether the acquisition is a business combination (IFRS 3) or an asset purchase. In a business combination, IPR&D is capitalised as an intangible asset (indefinite life, tested for impairment annually). In an asset purchase (buying a specific compound without associated workforce or processes), the payment is generally expensed as R&D immediately — the asset does not meet the IAS 38 recognition criteria at the point of acquisition for a pre-approval compound. Most pharmaceutical compound acquisitions are structured as asset purchases specifically to achieve R&D expensing.
⚠️ Audit Flags
Auditors perform the IFRS 3 vs. asset purchase analysis — this determination has massive income statement implications (capitalise vs. expense hundreds of millions). Key indicators of a business combination include the presence of a workforce, manufacturing capabilities, and self-sustaining processes at the acquired entity. Test the fair value allocation in any business combination acquisition — IPR&D fair value requires specialist valuation (probability-adjusted discounted cash flows by indication). Confirm that post-acquisition IPR&D is appropriately expensed on the acquired programs.
📄 Required Documentation
Acquisition agreement, IFRS 3 vs. asset purchase analysis, business combination purchase price allocation report (Big Four or specialist valuer), IPR&D fair value methodology (probability-adjusted DCF by indication and stage), subsequent R&D expense policy for acquired programmes, and impairment testing for capitalised IPR&D.
Professional Excel Template
Get the automated version of this entry. Includes built-in IFRS checks, VAT calculators, and SAP-ready upload formats.
Expert Analysis by Qusai Ahmad
General Accountant Supervisor & IFRS Specialist
Specialized in SAP GUI automation and Middle Eastern tax compliance. Building digital tools for the next generation of finance leaders.